Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate EC-18 for Oral Mucositis in Patients With Concomitant Chemoirradiation for Cancers of the Mouth, Oropharynx, Hypopharynx and Nasopharynx
Phase of Trial: Phase II
Latest Information Update: 18 May 2018
At a glance
- Drugs Mosedipimod (Primary)
- Indications Stomatitis
- Focus Adverse reactions
- Sponsors Enzychem Lifesciences Corporation
- 07 May 2018 Status changed from not yet recruiting to recruiting.
- 02 Aug 2017 According to an Enzychem Lifesciences Corporation media release, FDA has granted the company to start this phase II trial.
- 30 Jun 2017 New trial record